Physician profile
Antonio Luza
NPI 1891773834
$26,423.90
in general payments reported to CMS, 2019-2025
42 companies · $7,238 in 2025
The $7,238 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,080 · 2022: $6,106 · 2023: $4,348 · 2024: $3,652 · 2025: $7,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,480 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,756.48 |
| Consulting Fee | $1,480.00 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,947.89 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $2,830.57 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $2,297.25 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $2,244.24 | 2021-2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $2,184.63 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $1,892.28 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,635.38 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,604.26 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,263.09 | 2021-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $1,231.62 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,054.50 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $748.77 | 2021-2025 | Trintellix |
| Lundbeck LLC | $646.50 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $567.03 | 2023-2025 | Zepbound, Amyvid, Emgality |
| Exact Sciences Corporation | $415.58 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $282.76 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.15 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.83 | 2023-2025 | |
| Indivior INC. | $244.18 | 2021-2024 | Perseris |
| Bausch Health US, LLC | $241.36 | 2021-2025 | Aplenzin |
| Eisai INC. | $222.09 | 2021-2022 | |
| Ucb, INC. | $209.95 | 2021-2025 | Fintepla |
| Astrazeneca Pharmaceuticals LP | $208.15 | 2021-2025 | Breztri |
| Axsome Therapeutics, INC. | $136.07 | 2023-2025 | Auvelity |
| Neuronetics, INC. | $123.07 | 2023 | Neurostar Tms Therapy System |
| Merck Sharp & Dohme LLC | $111.35 | 2021-2022 | |
| Dexcom, INC. | $92.15 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Avanir Pharmaceuticals, INC. | $55.84 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.17 | 2023-2024 | Xifaxan |
| Alfasigma USA, INC. | $41.75 | 2022 | |
| Amgen INC. | $40.59 | 2025 | Otezla, Repatha |
| Luye Pharma (USA) LTD. | $39.17 | 2025 | Erzofri Extended-Release |
| Novo Nordisk INC | $34.95 | 2022-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $28.29 | 2025 | Trelegy Ellipta |
| Vertex Pharmaceuticals Incorporated | $26.12 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.41 | 2022 | |
| Scilex Pharmaceuticals INC. | $23.96 | 2025 | |
| Pfizer INC. | $22.39 | 2024 | |
| Idorsia Pharmaceuticals US INC | $22.05 | 2023 | Quviviq |
| Neurelis, INC. | $19.46 | 2025 | Valtoco |
| Collegium Pharmaceutical, INC. | $18.25 | 2023 | Belbuca |
| Celgene Corporation | $13.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Luza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.